Aerie pharmaceuticals to announce fourth quarter and year end 2013 financial results and host conference call on tuesday, march 18, 2014

Bedminster, n.j. & research triangle park, n.c. & newport beach, calif.--(business wire)--aerie pharmaceuticals, inc. (nasdaq: aeri) announced today that its fourth quarter and year end 2013 financial results will be released after the market closes on tuesday, march 18, 2014. following the release, aerie will host a live conference call and webcast at 5:00 p.m. eastern time to discuss the company’s financial results and provide a general business update. the live webcast and a replay may be accessed by visiting aerie's website at http://investors.aeriepharma.com. please connect to the company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. alternatively, please call (888) 734-0328 (u.s.) or (678) 894-3054 (international) to listen to the live conference call. the conference id number for the live call is 5403263. please dial in approximately 10 minutes prior to the call. telephone replay will be available approximately two hours after the call. to access the replay, please call 1-855-859-2056 (u.s.) or 404-537-3406 (international). the conference id number for the replay is 5403263. the telephone replay will be available until march 25, 2014. about aerie pharmaceuticals aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies. the company is preparing for two phase 3 registration trials, where the primary efficacy endpoint will be to demonstrate non-inferiority of iop lowering for ar-13324 (dosed once daily) compared to timolol (dosed twice daily). the company also started a phase 2b clinical trial of its fixed-dose combination product pg324, where the primary efficacy endpoint will be to demonstrate superiority of pg324 to each of its components.
AERI Ratings Summary
AERI Quant Ranking